Test Price
2,800 AED✅ Home Collection Available
IMPAD1 Gene NGS Test for Chondrodysplasia with Joint Dislocations (GPAPP Type)
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via NGS technology with ISO 9001:2015 accredited processing.
- Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test consultation with a qualified genetic counselor to support result interpretation.
- Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing (NGS) test analyzes the IMPAD1 gene to detect pathogenic variants responsible for chondrodysplasia with joint dislocations (GPAPP type), a severe skeletal dysplasia characterized by patellar aplasia or hypoplasia, progressive joint laxity, and characteristic radiographic findings. Molecular confirmation enables accurate prognosis, tailored orthopedic surveillance, and informed reproductive counseling for affected families.
| Feature | NGS Gold Standard | Conventional Sanger Sequencing |
|---|---|---|
| Precision | 99.9% sensitivity; full gene coverage with CNV detection | ~95% for point mutations; misses large deletions and duplications |
| Methodology | Next-generation sequencing with Sanger confirmation | Sanger sequencing of targeted exons only |
| Turnaround Time | 3–4 weeks | 4–6 weeks (frequently outsourced) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh — Consultant Medical Genetics (DHA Registration ID: 9294403): "The IMPAD1 gene test delivers definitive molecular diagnosis for a challenging skeletal dysplasia phenotype. Parents and clinicians gain clarity that transforms uncertainty into a targeted care pathway. I remind all families that genetic findings must be correlated with clinical and radiographic assessments by a specialist experienced in skeletal dysplasias."
Medication Advisory
Do not alter, pause, or discontinue any prescribed medications without prior consultation with your treating physician. This genetic test provides diagnostic information and does not replace ongoing clinical management.
Safety Exclusion Criteria & Emergency Red Flags
- This genetic test is not indicated for the evaluation of acute joint trauma, septic arthritis, or infectious causes of joint dislocation.
- Required specimen: peripheral whole blood or extracted DNA. Patients with known bleeding disorders should inform our collection team in advance.
- Emergency red flag: Sudden joint dislocation accompanied by neurovascular compromise (pallor, pulselessness, numbness, or paralysis) requires immediate emergency medical evaluation. Do not delay emergency care while awaiting genetic results.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of IMPAD1 gene testing?
IMPAD1 sequencing identifies pathogenic mutations causing chondrodysplasia with joint dislocations (GPAPP type), enabling accurate diagnosis, prognosis, and recurrence risk assessment for family planning. Result interpretation requires correlation with radiographic and clinical findings.
2. How is the sample collected and what is the turnaround time?
A certified phlebotomist collects a peripheral blood sample during a VIP mobile home visit. The specimen is transported via temperature-controlled cold chain to our ISO 9001:2015 accredited laboratory. Results are delivered within 3–4 weeks from sample receipt.
3. Is this test covered by UAE health insurance?
Many UAE health insurers provide coverage for molecular genetic testing when medically indicated for symptomatic individuals with clinical features of skeletal dysplasia. We offer direct billing verification via WhatsApp at +971 54 548 8731 prior to scheduling your collection appointment.
4. Are home collection services safe for a child with known joint instability?
Yes. Our mobile phlebotomy team is trained in pediatric and special-needs collection techniques. However, if your child has severe joint laxity or a bleeding disorder, please advise our team beforehand so we can adjust the collection approach or coordinate with your treating hospital.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Patient Privacy
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Our facility is DHA-licensed (License No. 1143), ISO 9001:2015 certified, and follows strict data governance protocols to safeguard your genetic information. All results are released only to the ordering physician or authorized patient designee.
Clinical & Logistical Metadata
| Test Name | IMPAD1 Gene NGS Test for Chondrodysplasia with Joint Dislocations (GPAPP Type) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (21–28 Business Days) |
| Sample Type / Matrix | Peripheral Whole Blood or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | Q78.8 (Other specified osteochondrodysplasias) |
| LOINC Code | 21636-6 (Genetic analysis by Sequencing) |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians